Wave Neuroscience
Wave Neuroscience is a private neuromodulation company that develops MeRT, an FDA-cleared EEG-guided transcranial magnetic stimulation system for PTSD and related neurological conditions, distributed through a provider network of 60+ US clinics across 23 states and 10+ international markets.
- Company typePrivate
- Founded2019
- HeadquartersNewport Beach, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Wave Neuroscience does
Wave Neuroscience is a private, Newport Beach-based neurotechnology company founded in 2019 that has developed MeRT (Magnetic e-Resonance Therapy), a personalized neuromodulation platform combining rapid quantitative EEG assessments with customized Transcranial Magnetic Stimulation (TMS). The system uses proprietary algorithms to analyze EEG-derived brain activity biomarkers and generate individualized treatment parameters, supported by a database of 60,000+ brainwave recordings that underpins the company's Braincare analysis platform. In June 2026, MeRT became the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for the treatment of PTSD in adults, following an FDA Breakthrough Device Designation awarded in December 2024 and supported by a 158-patient double-blinded randomized controlled multisite trial conducted with Texas A&M Health.
The company operates a B2B distribution model, licensing MeRT technology, protocols, and training to a network of independently owned and operated clinics rather than selling directly to consumers. Its provider footprint spans 60+ US clinic locations across 23 states plus international providers in 10+ countries, augmented by a channel partnership with Restore Hyper Wellness (225+ studios across 40 states) that extends the consumer-facing Braincare offering into the wellness and performance segment. Key customer segments include military veterans and first responders (the primary clinical segment), adults with neuropsychiatric conditions, performance optimization seekers (e.g., professional athletes), and pediatric neurodevelopmental research (autism spectrum disorder). The company also holds assets from the 2020 acquisition of NeoSync, including the NEST system designed for eventual home-use, signaling a longer-term product-line expansion beyond clinic-delivered TMS.
Wave Neuroscience firmographics
Firmographics- Name
- Wave Neuroscience
- Legal name
- Wave Neuroscience Inc.
- Website
- https://waveneuro.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Wave Neuroscience is a private neuromodulation company that develops MeRT, an FDA-cleared EEG-guided transcranial magnetic stimulation system for PTSD and related neurological conditions, distributed through a provider network of 60+ US clinics across 23 states and 10+ international markets.
- Ownership category
- akta.pro rank
Wave Neuroscience industry classification
Industry- Product category
- Personalized Neuromodulation Technology
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where Wave Neuroscience is headquartered
LocationHeadquarters
- HQ city
- Newport Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Wave Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- MeRT Treatment Services: Revenue generated through independent clinics and providers offering MeRT treatments to patients. The company provides technology and protocols to provider network.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Wave Neuroscience product offering
Product offeringCore offering
Wave Neuroscience develops the MeRT® (Magnetic e-Resonance Therapy) System, which combines rapid quantitative EEG (qEEG) assessments with personalized Transcranial Magnetic Stimulation (TMS) protocols guided by proprietary algorithms. The Braincare™ cloud platform processes brainwave recordings against a database of 60,000+ recordings to generate individualized treatment parameters. The company licenses these technologies and protocols to a global network of independent clinics and institutional partners rather than treating patients directly.
Product overview
Wave Neuroscience offers a unified SaaS platform centered on MeRT® (Magnetic e-Resonance Therapy), a patented personalized neuromodulation system. The platform consists of MeRT® as the core treatment product and Braincare™ as the assessment and analysis platform. Braincare™ leverages advanced EEG neuroimaging to evaluate brain function and generate personalized treatment protocols, which MeRT® then delivers through customized Transcranial Magnetic Stimulation. The system uses AI-driven analysis of brainwave data to individualize treatment frequencies, representing a shift from traditional one-size-fits-all neuromodulation approaches.
Differentiator
Problem solved
Functional benefit
Brands
- MeRT: Magnetic e-Resonance Therapy - FDA-cleared personalized neuromodulation technology combining EEG assessments with transcranial magnetic stimulation
- Braincare
Products and services
- MeRT® (Magnetic e-Resonance Therapy) FDA-cleared personalized neuromodulation system that combines rapid quantitative EEG (qEEG) assessments with electrocardiogram (EKG) to analyze brain network function and guide individualized Transcranial Magnetic Stimulation (TMS) protocols using proprietary AI algorithms; licensed to independent clinics for treating PTSD, TBI, depression, and other neurological conditions.
- Braincare™ Cloud-based analysis platform that processes EEG-derived brainwave recordings against a proprietary database of 60,000+ recordings to generate digital brain images and personalized treatment protocols with age/gender-matched comparisons, delivered as a SaaS to provider clinics and partner wellness studios.
Quantifiable outcome
- 63% PTSD symptom improvement (PCL-5 scale) with eTMS, more than 4 times better than standard TMS at 31%
- +3 more outcomes
Companies that use Wave Neuroscience
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Wave Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Wave Neuroscience partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and major.
- Texas A&M Health Institute of Biosciences and TechnologycorePartnership for double-blinded randomized controlled multisite clinical trial supporting FDA clearance for MeRT system for PTSD. Trial demonstrated significant and clinically meaningful reductions in PTSD symptom severity with 158 patients enrolled.
- Virginia TechcoreClinical trial sponsor for eTMS (MeRT) for Veterans and First Responders With PTSD. Trial currently recruiting with estimated enrollment of 20 participants.
- Ohio Department of Mental Health and Addiction Services (OMAS)coreOhio state program implementing eTMS for veterans and first responders. Over 800 individuals treated with outcomes tracked through real-time data dashboard. Senator Frank Hoagland advocacy for legislative support.
- Wright State Universitycore$160,000 funding for stage 1 clinical trial on eTMS safety for PTSD treatment in military veterans and first responders. Dr. Matt Sherwood leading research with team of graduate students.
- Restore Hyper WellnessmajorRestore Hyper Wellness, with 225+ studios in 40 states, partnered with Wave Neuro to offer Braincare technology. Winner of Restore's 2023 Technology Award recognizing innovative technology leader.
- SOCOM and Department of DefensecoreMeRT-TBI-005 clinical trial evaluating safety and efficacy of MeRT for Persistent Post-Concussive Symptoms in service members.
- NeoSynccoreWave Neuroscience acquired NeoSync's technology assets including NEST system. NEST is designed for eventual home-use, expanding accessibility to neuromodulation treatment.
- SOC-F and TCS (Special Operations Care Fund and Tomahawk Charitable Solutions)coreCollaboration to facilitate treatment by BTC San Diego of Special Operations Forces veterans struggling with lack of focus, chronic sleep disruption, and cognitive fog. 18-month program.
- Global SOF FoundationcoreFoundation championed Wave Neuro's technology for treating SOF veterans with TBI and PTSD, resulting in Congressional Bill H.R. 1162 'No Hero Left Untreated' for VA pilot program.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Wave Neuroscience competitors and assessment
Company assessmentDirect peers
- Neuronetics: Neuronetics manufactures NeuroStar, the leading FDA-cleared TMS device primarily indicated for depression. Direct competitor in TMS-based neuromodulation with overlapping physician and clinic channels in the U.S.
- Brainsway: Brainsway develops deep TMS systems (H-coil) with FDA clearances for depression, OCD, and smoking cessation. Direct competitor in non-invasive TMS neuromodulation, especially in psychiatric indications.
- Magstim: Magstim manufactures TMS stimulators and coils used widely in research and clinical practice. Direct competitor in the TMS device market, particularly in neurology and psychiatry research settings.
- MagVenture: MagVenture produces FDA-cleared TMS systems for depression and clinical research applications. Direct peer offering TMS equipment to similar physician and clinic customers.
- Soterix Medical: Soterix Medical develops non-invasive brain stimulation platforms including TMS and tDCS for research and clinical use. Direct peer in the non-invasive neuromodulation device market.
- Neurosoft: Neurosoft manufactures TMS devices (e.g., Neuro-MS) for depression and neurological disorders, primarily serving European and international markets. Direct peer in non-invasive TMS hardware with comparable indications.
- Fisher Wallace: Fisher Wallace markets wearable cranial electrotherapy stimulators for depression, anxiety, and insomnia. Direct peer in non-invasive, at-home brain stimulation for psychiatric indications.
Emerging players
- Alto Neuroscience: Alto Neuroscience develops biomarker-guided therapeutics for depression and other psychiatric conditions. Emerging peer operating in the same personalized-mental-health category with overlapping patient populations.
- Big Health: Big Health builds digital therapeutics (Sleepio, Daylight) for insomnia and anxiety, often comorbid with PTSD/depression. Emerging peer addressing the same mental-health patient base via non-pharmacological approaches.
- Apollo Neuroscience: Apollo Neuroscience produces a wearable that delivers low-frequency vibration to improve sleep, focus, and stress resilience. Emerging peer in the consumer-facing, non-invasive brain stimulation category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Wave Neuroscience social profiles
Digital presenceWave Neuroscience compliance and trust
Trust signalCompliance2 records
Wave Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wave Neuroscience leadership team
Management profileNumber of profiles
Profiles3 records
Wave Neuroscience funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wave Neuroscience M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wave Neuroscience
What does Wave Neuroscience do?
Wave Neuroscience develops the MeRT® (Magnetic e-Resonance Therapy) System, which combines rapid quantitative EEG (qEEG) assessments with personalized Transcranial Magnetic Stimulation (TMS) protocols guided by proprietary algorithms. The Braincare™ cloud platform processes brainwave recordings against a database of 60,000+ recordings to generate individualized treatment parameters. The company licenses these technologies and protocols to a global network of independent clinics and institutional partners rather than treating patients directly.
Is Wave Neuroscience a public or private company?
Wave Neuroscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Wave Neuroscience founded?
Wave Neuroscience was founded in 2019. It employs 51 to 100 people.
Where is Wave Neuroscience based?
Wave Neuroscience is headquartered in Newport Beach, United States, in the North America region.
How does Wave Neuroscience make money?
One revenue line is on record: meRT Treatment Services.
Who are Wave Neuroscience's main competitors?
Direct peers on record are Neuronetics, Brainsway, Magstim, MagVenture, Soterix Medical, Neurosoft and Fisher Wallace. Emerging players are Alto Neuroscience, Big Health and Apollo Neuroscience.
Does Wave Neuroscience have an API?
No public API is recorded for Wave Neuroscience.
What industry is Wave Neuroscience in?
Wave Neuroscience's product category is Personalized Neuromodulation Technology. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.